abrdn Life Sciences Investors
HQL
66 hedge funds and large institutions have $60.6M invested in abrdn Life Sciences Investors in 2022 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 22 increasing their positions, 20 reducing their positions, and 10 closing their positions.
10% more repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 20
0% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 10
0.88% less ownership
Funds ownership: 15.96% → 15.07% (-0.88%)
1% less funds holding
Funds holding: 67 → 66 (-1)
43% less capital inflows, than outflows
Capital inflows: $4.22M | Capital outflows: $7.42M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$919K |
| 2 |
Wolverine Asset Management
Chicago,
Illinois
|
+$424K |
| 3 |
180 Wealth Advisors
Federal Way,
Washington
|
+$285K |
| 4 |
Shaker Financial Services
Arlington,
Virginia
|
+$280K |
| 5 |
Raymond James Financial Services Advisors
St. Petersburg,
Florida
|
+$229K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Cohen & Steers
New York
|
-$1.03M |
| 2 |
Raymond James & Associates
St Petersburg,
Florida
|
-$984K |
| 3 |
Stephens Inc
Little Rock,
Arkansas
|
-$949K |
| 4 |
Advisors Asset Management
Monument,
Colorado
|
-$797K |
| 5 |
Weiss Asset Management
Boston,
Massachusetts
|
-$377K |
HQL Hedge Fund Activity: Q1 2022 in Review
66 of the 6,363 institutional investors tracked by Wall St. Rank reported a position in abrdn Life Sciences Investors (HQL) for Q1 2022, worth a combined $60.6M — down 19% from $74.4M a quarter earlier.
Fund positioning in HQL was balanced in Q1 2022: 10 funds opened new positions, 10 closed out, 22 added to existing stakes and 20 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $919K. The largest seller was Cohen & Steers, cutting an estimated $1.03M.
- 66 institutional investors held abrdn Life Sciences Investors (HQL) as of Q1 2022, down from 67 in Q4 2021.
- Funds reported $60.6M of abrdn Life Sciences Investors stock for Q1 2022, down 19% quarter-over-quarter.
- 10 funds opened new abrdn Life Sciences Investors positions in Q1 2022 and 10 closed out, a net change of 0 holders.
- The largest abrdn Life Sciences Investors buyer in Q1 2022 was Morgan Stanley, an estimated $919K added.
- The largest abrdn Life Sciences Investors seller in Q1 2022 was Cohen & Steers, an estimated $1.03M sold.
Based on aggregated 13F filings for Q1 2022.